Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals has announced a change in its company secretary and registered office as of January 2025. Ben Harber has resigned as Company Secretary, with Westend Corporate LLP taking over the role. Additionally, the company has relocated its registered office to 6 Heddon Street, London. These changes reflect the company’s ongoing efforts to streamline operations and enhance its corporate structure.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company based in London, with subsidiaries in New York City. The company is focused on developing innovative therapies for blood and autoimmune diseases, aiming to expand the reach of bone marrow transplantation for patients with currently incurable life-threatening conditions.
Average Trading Volume: 33,049
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £14.19M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.
